Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 248

1.

Prevalence of osteonecrosis of the jaw in patients with oral bisphosphonate exposure.

Lo JC, O'Ryan FS, Gordon NP, Yang J, Hui RL, Martin D, Hutchinson M, Lathon PV, Sanchez G, Silver P, Chandra M, McCloskey CA, Staffa JA, Willy M, Selby JV, Go AS; Predicting Risk of Osteonecrosis of the Jaw with Oral Bisphosphonate Exposure (PROBE) Investigators.

J Oral Maxillofac Surg. 2010 Feb;68(2):243-53. doi: 10.1016/j.joms.2009.03.050. Epub 2009 Sep 24.

PMID:
19772941
2.
3.

Bisphosphonates and osteonecrosis of the jaw: a retrospective study.

Murad OM, Arora S, Farag AF, Guber HA.

Endocr Pract. 2007 May-Jun;13(3):232-8.

PMID:
17599853
4.

Intravenous bisphosphonate-related osteonecrosis of the jaw: bone scintigraphy as an early indicator.

O'Ryan FS, Khoury S, Liao W, Han MM, Hui RL, Baer D, Martin D, Liberty D, Lo JC.

J Oral Maxillofac Surg. 2009 Jul;67(7):1363-72. doi: 10.1016/j.joms.2009.03.005.

PMID:
19531404
5.

Clinical investigation of C-terminal cross-linking telopeptide test in prevention and management of bisphosphonate-associated osteonecrosis of the jaws.

Kunchur R, Need A, Hughes T, Goss A.

J Oral Maxillofac Surg. 2009 Jun;67(6):1167-73. doi: 10.1016/j.joms.2009.02.004.

PMID:
19446200
6.

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

Mavrokokki T, Cheng A, Stein B, Goss A.

J Oral Maxillofac Surg. 2007 Mar;65(3):415-23.

PMID:
17307586
7.

Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw: an institutional inquiry.

Sedghizadeh PP, Stanley K, Caligiuri M, Hofkes S, Lowry B, Shuler CF.

J Am Dent Assoc. 2009 Jan;140(1):61-6.

PMID:
19119168
8.

Prevalence and risk factors of bisphosphonate-associated osteonecrosis of the jaw in prostate cancer patients with advanced disease treated with zoledronate.

Walter C, Al-Nawas B, Grötz KA, Thomas C, Thüroff JW, Zinser V, Gamm H, Beck J, Wagner W.

Eur Urol. 2008 Nov;54(5):1066-72. doi: 10.1016/j.eururo.2008.06.070. Epub 2008 Jun 26.

PMID:
18602738
10.

Osteonecrosis of the jaw in Sweden associated with the oral use of bisphosphonate.

Ulmner M, Jarnbring F, Törring O.

J Oral Maxillofac Surg. 2014 Jan;72(1):76-82. doi: 10.1016/j.joms.2013.06.221. Epub 2013 Aug 29.

PMID:
23992777
11.

[Osteonecrosis of the jaw developing during bisphosphonate treatment].

Udvardy E, Redl P, Márton I.

Magy Onkol. 2008 Mar;52(1):81-7. doi: 10.1556/MOnkol.52.2008.1.12. Review. Hungarian.

PMID:
18403302
12.

Risk factors for osteonecrosis of the jaws: a case-control study from the CONDOR dental PBRN.

Barasch A, Cunha-Cruz J, Curro FA, Hujoel P, Sung AH, Vena D, Voinea-Griffin AE; CONDOR Collaborative Group, Beadnell S, Craig RG, DeRouen T, Desaranayake A, Gilbert A, Gilbert GH, Goldberg K, Hauley R, Hashimoto M, Holmes J, Latzke B, Leroux B, Lindblad A, Richman J, Safford M, Ship J, Thompson VP, Williams OD, Yin W.

J Dent Res. 2011 Apr;90(4):439-44. doi: 10.1177/0022034510397196. Epub 2011 Feb 11.

13.

Canadian consensus practice guidelines for bisphosphonate associated osteonecrosis of the jaw.

Khan AA, Sándor GK, Dore E, Morrison AD, Alsahli M, Amin F, Peters E, Hanley DA, Chaudry SR, Dempster DW, Glorieux FH, Neville AJ, Talwar RM, Clokie CM, Al Mardini M, Paul T, Khosla S, Josse RG, Sutherland S, Lam DK, Carmichael RP, Blanas N, Kendler D, Petak S, St-Marie LG, Brown J, Evans AW, Rios L, Compston JE; Canadian Association of Oral and Maxillofacial Surgeons.

J Rheumatol. 2008 Jul;35(7):1391-7. Epub 2008 Jun 1. Erratum in: J Rheumatol. 2008 Oct;35(10):2084. J Rheumatol. 2008 Aug;35(8):1688.

PMID:
18528958
14.

Risk of osteonecrosis of the jaw in cancer patients taking bisphosphonates.

Gebara SN, Moubayed H.

Am J Health Syst Pharm. 2009 Sep 1;66(17):1541-7. doi: 10.2146/ajhp080251. Review.

PMID:
19710437
15.

Oral health considerations in older women receiving oral bisphosphonate therapy.

Lo JC, O'Ryan F, Yang J, Hararah MK, Gonzalez JR, Gordon N, Silver P, Ansfield A, Wang B, Go AS.

J Am Geriatr Soc. 2011 May;59(5):916-22. doi: 10.1111/j.1532-5415.2011.03371.x. Epub 2011 May 3.

PMID:
21539523
16.

Osteonecrosis of the jaws associated with use of risedronate: report of 2 new cases.

Brooks JK, Gilson AJ, Sindler AJ, Ashman SG, Schwartz KG, Nikitakis NG.

Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2007 Jun;103(6):780-6. Epub 2007 Jan 12.

PMID:
17223592
17.

Osteonecrosis of the jaw in patients receiving intravenous or oral bisphosphonates.

King AE, Umland EM.

Pharmacotherapy. 2008 May;28(5):667-77. doi: 10.1592/phco.28.5.667. Review.

PMID:
18447663
18.

Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.

Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K.

J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5.

PMID:
19805682
19.

Osteonecrosis of the jaw in cancer patients receiving IV bisphosphonates.

Van Poznak C, Estilo C.

Oncology (Williston Park). 2006 Aug;20(9):1053-62; discussion 1065-6. Review.

20.

Outcomes of placing dental implants in patients taking oral bisphosphonates: a review of 115 cases.

Grant BT, Amenedo C, Freeman K, Kraut RA.

J Oral Maxillofac Surg. 2008 Feb;66(2):223-30. doi: 10.1016/j.joms.2007.09.019.

PMID:
18201600

Supplemental Content

Support Center